Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary.

Journal Article (Journal Article)

OBJECTIVE: To review the primary and secondary findings from the Multimodal Treatment study of ADHD (MTA) published over the past decade as three sets of articles. METHOD: In a two-part article-Part I: Executive Summary (without distracting details) and Part II: Supporting Details (with additional background and detail required by the complexity of the MTA)-we address confusion and controversy about the findings. RESULTS: We discuss the basic features of the gold standard used to produce scientific evidence, the randomized clinical trial, for which was used to contrast four treatment conditions: medication management alone (MedMgt), behavior therapy alone (Beh), the combination of these two (Comb), and a community comparison of treatment "as usual" (CC). For each of the three assessment points we review three areas that we believe are important for appreciation of the findings: definition of evidence from the MTA, interpretation of the serial presentations of findings at each assessment point with a different definition of long-term, and qualification of the interim conclusions about long-term effects of treatments for ADHD. CONCLUSION: We discuss the possible clinical relevance of the MTA and present some practical suggestions based on current knowledge and uncertainties facing families, clinicians, and investigators regarding the long-term use of stimulant medication and behavioral therapy in the treatment of children with ADHD.

Full Text

Duke Authors

Cited Authors

  • Swanson, J; Arnold, LE; Kraemer, H; Hechtman, L; Molina, B; Hinshaw, S; Vitiello, B; Jensen, P; Steinhoff, K; Lerner, M; Greenhill, L; Abikoff, H; Wells, K; Epstein, J; Elliott, G; Newcorn, J; Hoza, B; Wigal, T; MTA Cooperative Group,

Published Date

  • July 2008

Published In

Volume / Issue

  • 12 / 1

Start / End Page

  • 4 - 14

PubMed ID

  • 18573923

Pubmed Central ID

  • 18573923

International Standard Serial Number (ISSN)

  • 1087-0547

Digital Object Identifier (DOI)

  • 10.1177/1087054708319345


  • eng

Conference Location

  • United States